ATE272117T1 - Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie - Google Patents

Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Info

Publication number
ATE272117T1
ATE272117T1 AT94925523T AT94925523T ATE272117T1 AT E272117 T1 ATE272117 T1 AT E272117T1 AT 94925523 T AT94925523 T AT 94925523T AT 94925523 T AT94925523 T AT 94925523T AT E272117 T1 ATE272117 T1 AT E272117T1
Authority
AT
Austria
Prior art keywords
monocyte
cell line
gene therapy
recombinant cells
macrophage cell
Prior art date
Application number
AT94925523T
Other languages
English (en)
Inventor
Hedi Haddada
Manuel Lopez
Michel Perricaudet
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE272117T1 publication Critical patent/ATE272117T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94925523T 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie ATE272117T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9310222A FR2709309B1 (fr) 1993-08-25 1993-08-25 Compositions cellulaires, préparation et utilisations thérapeutiques.
PCT/FR1994/001019 WO1995006120A1 (fr) 1993-08-25 1994-08-22 Cellules recombinantes de la lignee monocyte-macrophage pour la therapie genique

Publications (1)

Publication Number Publication Date
ATE272117T1 true ATE272117T1 (de) 2004-08-15

Family

ID=9450378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925523T ATE272117T1 (de) 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Country Status (14)

Country Link
US (1) US6210963B1 (de)
EP (1) EP0719332B1 (de)
JP (1) JP3731035B2 (de)
KR (1) KR100392984B1 (de)
AT (1) ATE272117T1 (de)
AU (1) AU698043B2 (de)
CA (1) CA2170159A1 (de)
DE (1) DE69433921T2 (de)
FI (1) FI960855A (de)
FR (1) FR2709309B1 (de)
IL (1) IL110754A (de)
NO (1) NO319990B1 (de)
WO (1) WO1995006120A1 (de)
ZA (1) ZA946264B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
DE69734974D1 (de) * 1996-02-08 2006-02-02 Us Gov Health & Human Serv Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
GB2332434B (en) * 1996-10-09 2001-04-04 Oxford Biomedica Ltd Mononuclear phagocytes in therapeutic drug delivery
US20020068048A1 (en) * 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
NZ503318A (en) * 1997-09-23 2001-11-30 Oxford Biomedica Ltd Modified haemopoietic stem cell comprised of a spliced upstream with a nucleotide sequence of interest to be used as in gene therapy
EP1165754A1 (de) * 1999-04-06 2002-01-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmazeutische zusammensetzung enthaltend zirkulierende blutzellen, bevorzugt monocyten, und deren verwendung
WO2001087314A1 (en) * 2000-05-18 2001-11-22 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis using monocytes
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CA2425021A1 (en) * 2002-04-12 2003-10-12 Sumitomo Electric Industries, Ltd. Control of the ratio of lap to lip
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1638587A4 (de) 2003-02-14 2007-04-18 Univ Missouri Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
US20080038234A1 (en) * 2004-03-23 2008-02-14 Shuji Hayashi Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
EP2079830B1 (de) 2006-10-04 2016-08-17 Janssen Pharmaceutica NV Herstellung von zellen mit deaktivierten künstlichen antigenen und ihre verwendung in zelltherapien
US8202717B2 (en) 2007-01-12 2012-06-19 The Board Of Trustees Of The University Of Illinois Non-simian cells for growth of porcine reproductive and respiratory syndrome (PRRS) virus
JP5546107B2 (ja) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 RNAウイルスBmMLV陰性カイコ培養細胞株
EP2248903A1 (de) * 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
KR20160002971A (ko) 2013-04-18 2016-01-08 틸트 바이오세러퓨틱스 오이 향상된 입양 세포 치료
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3601539A4 (de) * 2017-03-28 2021-01-13 Zhenglun Zhu Verfahren zur behandlung von neoplastischen erkrankungen
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
BR112022003970A2 (pt) 2019-09-03 2022-06-21 Myeloid Therapeutics Inc Métodos e composições para integração genômica
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4240367A2 (de) 2020-11-04 2023-09-13 Myeloid Therapeutics, Inc. Manipulierte chimäre fusionsproteinzusammensetzungen und verfahren zur verwendung davon
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
CA1340565C (en) * 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
EP0667792A1 (de) * 1991-11-22 1995-08-23 The General Hospital Corporation Spezifische toleranz bei transplantation
US5338165A (en) * 1991-11-25 1994-08-16 Ford Motor Company Automotive fuel pump with modular pump housing
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
US5436151A (en) * 1992-04-03 1995-07-25 Regents Of The University Of Minnesota Method for culturing human hematopoietic stem cells in vitro
DE4219626A1 (de) * 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
ATE386800T1 (de) * 1993-03-17 2008-03-15 Us Gov Health & Human Serv Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors

Also Published As

Publication number Publication date
NO960743D0 (no) 1996-02-23
JP3731035B2 (ja) 2006-01-05
IL110754A0 (en) 1994-11-11
IL110754A (en) 2001-04-30
KR100392984B1 (ko) 2004-10-20
FR2709309B1 (fr) 1995-11-10
US6210963B1 (en) 2001-04-03
DE69433921T2 (de) 2006-10-05
AU7539894A (en) 1995-03-21
EP0719332B1 (de) 2004-07-28
WO1995006120A1 (fr) 1995-03-02
DE69433921D1 (de) 2004-09-02
FR2709309A1 (fr) 1995-03-03
NO960743L (no) 1996-03-25
AU698043B2 (en) 1998-10-22
CA2170159A1 (fr) 1995-03-02
JPH09501837A (ja) 1997-02-25
ZA946264B (en) 1995-03-20
EP0719332A1 (de) 1996-07-03
NO319990B1 (no) 2005-10-10
FI960855A0 (fi) 1996-02-23
FI960855A (fi) 1996-04-23

Similar Documents

Publication Publication Date Title
ATE272117T1 (de) Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie
Koi et al. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
DE69527540T2 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
DE69837393D1 (de) Stimulierung von hämatopoietischen zellen im vitro
ATE265219T1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE361668T1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
Facchetti et al. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
DE69333954D1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
ES2144626T3 (es) Uso de peptidos de adhesion celular para la modificacion del poder de adhesion de celulas eucarioticas entre si.
DE3855634D1 (de) Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen
DE69328832D1 (de) Zielelektrode zur verhinderung von korrision in elektrochemischen zellen
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
SE8605459D0 (sv) Novel cell growth regulatory factor
Haughn Tumor Cell Growth Arrest Caused by
AU1402495A (en) Use of macrophage depleting agents for prolonging the survival of non-autologus hematopoietic cell transplants and animal model assay systems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties